At Ensysce Biosciences' Annual Meeting on November 21, 2024, shareholders approved several key proposals, including authorization for a reverse stock split at a ratio between 1:10 and 1:40, to be determined by the Board. Stockholders also approved the issuance of common stock and exercise of warrants to certain investors in compliance with Nasdaq rules.Three Class III Directors were re-elected with terms expiring in 2027: Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin. The appointment of Moss Adams LLP as the company's independent registered public accounting firm for fiscal year 2024 was also ratified by shareholders.The voting results showed strong support for most proposals, with the reverse stock split receiving 4.56 million votes in favor versus 1.99 million against. The fifth proposal regarding meeting adjournment was not submitted to a vote.

At Ensysce Biosciences' Annual Meeting on November 21, 2024, shareholders approved several key proposals, including authorization for a reverse stock split at a ratio between 1:10 and 1:40, to be determined by the Board. Stockholders also approved the issuance of common stock and exercise of warrants to certain investors in compliance with Nasdaq rules.Three Class III Directors were re-elected with terms expiring in 2027: Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin. The appointment of Moss Adams LLP as the company's independent registered public accounting firm for fiscal year 2024 was also ratified by shareholders.The voting results showed strong support for most proposals, with the reverse stock split receiving 4.56 million votes in favor versus 1.99 million against. The fifth proposal regarding meeting adjournment was not submitted to a vote.